Dow, S&P 500 end lower; Eli Lilly shares fall after drug data

U.S. equities closed mixed, with the Dow and S&P 500 easing while the Nasdaq gained, as investors digested corporate news and political developments. Eli Lilly shares fell on disappointing drug trial data, and Intel dropped after former President Trump called for its CEO's resignation over alleged China ties, while Apple rose due to tariff exemptions for U.S.-based manufacturing. Broader market sentiment was also shaped by the implementation of new tariffs, reports of Trump's preferred Fed Chair candidate, and sustained high expectations for a September Fed rate cut despite a slight rise in jobless claims.

Analysis

U.S. equity markets exhibited divergent performance, with the Dow and S&P 500 declining while the Nasdaq posted gains, reflecting a market grappling with specific corporate catalysts and significant political developments. The broader market rally showed signs of fatigue amid the implementation of new tariffs that have elevated the average U.S. import duty to its highest level in a century. Company-specific news was a primary driver of volatility. Eli Lilly shares fell despite an increased full-year forecast, as investors reacted negatively to disappointing trial data for its oral weight loss drug, orforglipron. Similarly, Fortinet shares dropped after issuing a revenue forecast below Wall Street estimates. Geopolitical risk was highlighted by Intel's stock decline, which followed former President Trump's call for its CEO's resignation due to his alleged ties to Chinese firms. In contrast, Apple shares advanced, providing a key lift to the Nasdaq, after it was determined that Trump's new 100% tariff on semiconductors would largely exempt firms with U.S.-based manufacturing. Macroeconomic sentiment remains anchored to monetary policy expectations, with CME's FedWatch Tool indicating a 93.2% probability of a rate cut in September, a view supported by a modest rise in weekly jobless claims to 226,000.

Key Decisions for Investors

• Investors should closely monitor political rhetoric as a source of single-stock risk, as demonstrated by the negative impact on Intel's shares following comments from a political figure.
• Evaluate portfolio holdings based on their domestic manufacturing footprint, as the market is rewarding companies like Apple that are insulated from or benefit from the specific structure of new tariff policies.
• In the pharmaceutical sector, recognize that clinical trial data can outweigh positive forward guidance, as seen with Eli Lilly's stock decline despite its raised profit and sales forecast.
• Maintain awareness that despite broad tariff headwinds, market sentiment is heavily influenced by expectations for a Fed rate cut, making positions sensitive to shifts in monetary policy signals or economic data like jobless claims.